# A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

> **NCT07794774** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 197 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Berobenatide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07794774
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-28
- **Primary completion:** 2029-02-21
- **Final completion:** 2029-02-21
- **Target enrollment:** 197 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07794774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07794774, "A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07794774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
